我武生物(300357.SZ):“黃花蒿花粉點刺液”的上市許可申請已獲正式受理
格隆匯12月22日丨我武生物(300357.SZ)公佈,日前,公司獲得國家藥品監督管理局發出的《受理通知書》,由公司提交註冊的“黃花蒿花粉點刺液”上市許可申請已獲得正式受理。
適應症:用於點刺試驗,輔助診斷因黃花蒿/艾蒿花粉致敏引起的I型變態反應性疾病。
“黃花蒿花粉點刺液”與公司已上市的“粉塵蟎皮膚點刺診斷試劑盒”(國藥準字S20080010)、“屋塵蟎皮膚點刺診斷試劑盒”(國藥準字S20190022)產品互為補充,可以滿足更多過敏性疾病患者的過敏原檢測需求。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.